Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

about

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.

P2860

Q55037961-9981218A-15F3-4401-981A-CC7CDD314608

P2860

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

Item

http://www.wikidata.org/entity/Q50204127

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

@en

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

@nl

type

Item

label

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

@en

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

@nl

prefLabel

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

@en

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

@nl

P1476

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

@en

P2093

Deanna L Kroetz

http://www.w3.org/2001/XMLSchema#string

Megan Li

http://www.w3.org/2001/XMLSchema#string

P2860

Framingham Heart Study 100K Project: genome-wide associations for blood pressure and arterial stiffness

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

Rare independent mutations in renal salt handling genes contribute to blood pressure variation

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk

VEGF inhibition and renal thrombotic microangiopathy

Endothelin and endothelin receptors in the renal and cardiovascular systems

Secondary arterial hypertension: when, who, and how to screen?

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

The biology of VEGF and its receptors

P304

152-160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PHARMTHERA.2017.08.012

http://www.w3.org/2001/XMLSchema#string

P478

182

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28882537

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5785435

http://www.w3.org/2001/XMLSchema#string

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

about

P2860

P2860

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932